Hepatic non-Hodgkin lymphoma and hepatoblastoma complicating ataxia-telangiectasia.

Abstract

Patients with ataxia-telangiectasia (A-T) have an increased risk of developing malignancies and are prone to severe early or late toxicity owing to chemotherapy. Leukemia and lymphoma account for about 85% of malignancies, but solid tumors have also been reported. We describe an unusual case of an 8-year-old child affected by A-T, who presented a primary hepatic B-cell non-Hodgkin lymphoma, treated with reduced doses of R-CHOP cycles plus rituximab. Three years later, the patient developed hepatoblastoma as a second malignancy. This case clearly emphasizes the need for intensive monitoring of A-T patients for early signs of malignancy and the opportunity to consider specific and modified regimens of chemotherapy.

• Authors: Valerio Cecinati, Giampaolo Arcamone, Domenico De Mattia, Nicola Santoro, Baldassarre Martire
• Journal: Immunopharmacology and immunotoxicology (Immunopharmacol Immunotoxicol) Vol. 34 Issue 1 Pg. 1-3 (Feb 2012) ISSN: 1532-2513 [Electronic] England
• PMID: 21457128 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antibodies, Monoclonal, Murine-Derived
• Rituximab

Topics

• Antibodies, Monoclonal, Murine-Derived (administration & dosage)
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage)
• Ataxia Telangiectasia
• Child
• Child, Preschool
• Hepatoblastoma (therapy)
• Humans
• Liver Neoplasms (therapy)
• Lymphoma, Non-Hodgkin (therapy)
• Male
• Neoplasms, Second Primary (therapy)
• Rituximab